Last €76.40 EUR
Change Today -1.22 / -1.57%
Volume 110.2K
MOR On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
As of 3:35 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

morphosys ag (MOR) Snapshot

Open
€77.51
Previous Close
€77.61
Day High
€77.65
Day Low
€75.54
52 Week High
12/8/14 - €90.00
52 Week Low
04/15/14 - €53.70
Market Cap
2.0B
Average Volume 10 Days
135.6K
EPS TTM
€-0.22
Shares Outstanding
26.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MORPHOSYS AG (MOR)

Related News

No related news articles were found.

morphosys ag (MOR) Related Businessweek News

No Related Businessweek News Found

morphosys ag (MOR) Details

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies for therapeutic applications. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease. It operates therapeutic development programs for drug candidates in cooperation with various biotechnology and pharmaceutical companies, as well as focuses on the development of proprietary therapeutic antibodies. The company’s proprietary programs include MOR103, an antibody against GM-CSF for the treatment of rheumatoid arthritis and multiple sclerosis, as well as other proprietary clinical programs, including MOR202 and MOR208 for the treatment of cancer. It has strategic alliances with Novartis AG for the discovery and development of biopharmaceuticals; and Celgene Corporation for the development and co-promotion of the CD38 cancer program. The company was founded in 1992 and is headquartered in Martinsried, Germany.

328 Employees
Last Reported Date: 11/7/14
Founded in 1992

morphosys ag (MOR) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €772.6K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €524.1K
Chief Development Officer and Member of Manag...
Total Annual Compensation: €524.1K
Chief Scientific Officer and Member of Manage...
Total Annual Compensation: €524.1K
Compensation as of Fiscal Year 2013.

morphosys ag (MOR) Key Developments

Morphosys AG Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 04:30 PM

Morphosys AG Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 04:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Simon E. Moroney, Chairman of Management Board and Chief Executive Officer.

MorphoSys's Partner Roche Provides Update on Trial of Gantenerumab in Prodromal Alzheimer's Patients

MorphoSys AG was informed on December 19, 2014 that its partner Roche has decided to discontinue the phase 3 SCarletRoAD trial of gantenerumab in prodromal Alzheimer's Disease patients. The decision is based on a pre-planned futility analysis and a recommendation by the independent Data Monitoring Committee. According to Roche, no new safety signals were observed in the SCarletRoAD trial and the overall safety profile was similar to that seen in the phase 1 study. The second Roche-sponsored phase 3 trial of gantenerumab in mild Alzheimer's Disease patients (Marguerite RoAD) will continue. MorphoSys's partnered and proprietary clinical pipeline currently comprises 21 unique antibody molecules which are being evaluated in more than 60 clinical trials. In total, MorphoSys's product pipeline comprises 94 partnered and proprietary programs which are being evaluated in a broad range of indications. Gantenerumab, a fully human antibody targeting amyloid-beta, is in development for the treatment of Alzheimer's Disease. The discontinued SCarletRoAD study has enrolled 799 pre-symptomatic patients with so-called prodromal Alzheimer's Disease. Two additional clinical studies are currently ongoing. The Marguerite RoAD trial is a Phase 3 study evaluating gantenerumab in approx. 1,000 patients with mild Alzheimer's Disease. The second trial, run by the Dominantly Inherited Alzheimer Network (DIAN), assesses the safety, tolerability and biomarker efficacy of gantenerumab in individuals who have a genetic predisposition for Alzheimer's disease.

Morphosys AG Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Morphosys AG Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MOR:GR €76.40 EUR -1.22

MOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €10.45 EUR -0.07
Dyax Corp $15.79 USD +0.61
Genmab A/S kr441.30 DKK -1.70
ImmunoGen Inc $6.20 USD +0.03
Intrexon Corp $30.05 USD 0.00
View Industry Companies
 

Industry Analysis

MOR

Industry Average

Valuation MOR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 29.1x
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MORPHOSYS AG, please visit www.morphosys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.